Elevar Therapeutics Announces FDA Classification of New Drug Application Resubmission for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
[vc_row][vc_column][vc_column_text] FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE, N.J., Nov. 4 –